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The aim of the present study was to characterize biotin-decorated docetaxel-loaded bovine serum albumin 
nanoparticles (DTX-BIO-BSA-NPs) and evaluate their antiproliferative activity in vitro. The particle 
size of prepared DTX-BIO-BSA-NPs was found to be always lower than 200 nm, with sizes of 166.9, 
160.3, 159.0, 176.1 and 184.8 nm and the zeta potential was -29.51, -28.54, -36.54, -36.08 and -27.56 mV 
after redissolution with water for 0, 1, 2, 4 and 8 hours, respectively. The polydispersity index (PDI) was 
stable in the range of 0.170 - 0.178. In the in vitro drug-release study, the DTX-BIO-BSA-NPs targeted 
a human breast cancer cell line MCF-7 effectively. The x-ray diffraction spectrum and DSC curve of 
DTX-BIO-BSA-NPs suggested that docetaxel was in an amorphous or disordered crystalline phase in 
DTX-BIO-BSA-NPs. In vitro cytotoxicity results showed that DTX-BIO-BSA-NPs inhibits proliferation 
of MCF-7, SGC7901, LS-174T and A549 cells in a concentration-dependent manner after exposure to 
DTX-BIO-BSA-NPs for 48 hours. Taken together, these results indicate that DTX-BIO-BSA-NPs may 
have potential as an alternative delivery system for parenteral administration of docetaxel. 
Keywords: Albumin/nanoparticles/characterization. Docetaxel. Antiproliferative activities. Biotin. 
INTRODUCTION
Docetaxel (DTX) is a semi-synthetic, taxane-
derived, highly potent anticancer drug. It represents the 
second generation of taxane anticancer drugs and has 
shown broad spectrum antitumor activity against prostate, 
breast, pancreatic, lung, gastric and hepatic carcinomas 
(Xu et al., 2009; Hwang, 2012; Zhao, Astruc, 2012; Chen 
et al., 2016). Docetaxel binds irreversibly with b-actin and 
stabilizes the microtubule assembly which is responsible 
for inhibition of cell division and finally cell death 
(Musumeci et al., 2006). Therefore this drug is currently 
used as a first-line treatment in clinical chemotherapy. 
However, the current preparations of docetaxel have some 
drawbacks such as water-insolubility, sensitization and 
toxic side effects.
Nanoparticles are made of a variety of polymers, 
such as polysaccharides (Fernandez-Urrusuno et al., 1999; 
Liu et al., 2008), proteins (Elzoghby, 2013; Harsha 2013) 
and synthetic polymers (Fattal et al., 1998; Breunig, Bauer, 
Goepferich, 2008). Among all the available materials, 
biological molecules have attracted considerable interest 
for application to nanomedicine because they are fully 
biocompatible and water-soluble (Kratz, 2008). Biological 
molecules have several advantages over small molecules 
and polymers for biomedical applications. First, the water-
solubility of surface-modified nanoparticles generally 
increases with increasing mass of the ligands (Ackerson, 
Jadzinsky, Kornberg, 2005; Sperling, Parak, 2010) 
and thus, biological molecules will provide enhanced 
water-solubility for nanoparticles. Second, conjugating 
biological molecules to nanoparticles controls the release 
of drug in a sustained manner over a longer period of time 
(Roney et al., 2005).
As a water-soluble protein, serum albumin is the 
most abundant and basic protein of blood plasma. It 
is primarily involved in the transport of substances in 
the blood that are poorly soluble in water, including 
drugs, and also alters the disposition of endogenous 
and exogenous compounds present in blood (Moreno, 
Cortijo, Gonzalez-Jimenez, 1999). Albumin is also 
reported to associate with nanoscale particles to promote 
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their transportation through cells (Mehta et al., 2004; 
Zhang et al., 2008). Additionally, albumin nanoparticles 
exhibited high binding capacity of various drugs (Jithan 
et al., 2011; Kratz, 2014) and were well tolerated without 
any serious side effects (Ibrahim et al., 2002). Bovine 
serum albumin (BSA) is an important carrier protein in 
blood plasma for several ions and molecules. It is one of 
the most extensively-studied proteins and has structural 
homology to human serum albumin as a substitute 
for research (Yu et al., 2012). Accordingly, albumin 
nanoparticles have received considerable attention 
(Elzoghby, Samy, Elgindy, 2012). Encouragingly, a 
paclitaxel-loaded human serum albumin nanoparticles 
(AbraxaneÒ) was approved by FDA for clinical use in 
2005. It improved water solubility of paclitaxel with 
enhanced efficacy and tolerability compared with a 
Cremophor-based paclitaxel formulation (Cortes, Saura, 
2010). Targeted therapy is among the most attractive 
strategies for cancer, the major cause of death in most 
advanced countries in the world. Conventional cancer 
chemotherapy, which usually utilizes small molecule 
drugs, is far from successful, mostly due to the lack of 
tumor selectivity, which leads to dose-limiting toxicity, 
resulting severe adverse effects that limits usage. To 
overcome these drawbacks, targeted anticancer therapy 
is aims to have tumor-selective anticancer effects with 
less systemic side effects. To increase the delivery of a 
given drug to a specific target site, albumin can be surface 
conjugated using various targeting moieties or ligands, 
such as folate, saccharide, biotin and peptides. Among 
them, biotin is used widely as a tumor targeting ligand 
for various anti-cancer drugs.
Biotin (vitamin H) participates as a coenzyme 
in reactions involving CO2 such as carboxylations, 
transcarboxylations, and decarboxylations. Biotin 
is widely applied in two-step pretargeting strategies 
(Balthasar et al., 2005; Mårtensson et al., 2007; Lesch 
et al., 2010; Lindegren, Frost, 2011; Uppal et al., 2011; 
Marysael et al., 2012; Urbanska et al., 2012). Recent 
studies revealed that biotin receptors were over-expressed 
on numerous tumors characterized by rapid dividing and 
aggressive growth (Russell-Jones et al., 2004; Patel et al., 
2012; Li et al., 2013). 
In this paper, we introduced biotin ligand on the 
surface of docetaxel-loaded bovine serum albumin 
nanoparticles (DTX-BIO-BSA-NPs) in an attempt 
to specifically target the corresponding receptors of 
carcinoma. This study aimed to formulate DTX-BIO-
BSA-NPs and evaluate their physicochemical properties, 
measure in vitro release and determine their effectiveness 
in tumor cells.
MATERIAL AND METHODS
Material
Bovine serum albumin was provided by Instituto 
Grifols, S.A. (Barcelona, Spain). The docetaxel was 
obtained from Shanghai Kairen Bio-Technology Co. 
Ltd (Shanghai, China). Fetal calf serum was obtained 
from Shanghai Solarbio Biosience and techolgo Co. Ltd 
(Shanghai, China). Phosphate-buffered saline (pH7.4) and 
trypsin were purchased from Sigma Chemicals Co. (St. 
Louis, USA). Fluorescein isothiocyanate (FITC) and Lyso-
Tracker Red were purchased from Beyotime Institute of 
Biotechnology (Haimen, China). RPMI 1640 medium was 
obtained from HyClone Inc. (Logan, USA). Acetonitrile 
and methanol (HPLC-grade) were obtained from J&K 
Chemical Ltd (Beijing, China). Water was collected from 
a Milli-Q organic free water system (Millipore, Bedford, 
USA). All the other chemical agents and chemicals were 
used as analytic reagents.
Preparation of DTX-BIO-BSA-NPs 
The DTX-BIO-BSA-NPs were prepared as 
previously described using a desolvation technique (Jun 
et al., 2011). Briefly, 75 mg bovine serum albumin was 
first dissolved in 7.5 mL deionized water, then 33.75 
mg docetaxel dissolved in 22.5 mL ethanol was added 
using a peristaltic pump BT01-100 (Kejian, Changzhou, 
China) at room temperature (1 mL/min). Afterwards, 
220 mL of 0.25% (v/v) glutaraldehyde was added to 
the resultant solution for amino groups crosslink in the 
nanoparticles. The cross-linking process was performed 
during stirring of the suspension for 15 h. The organic 
reagents were removed by evaporation using a rotary 
evaporator RE-52AA (Yarong, Shanghai, China) at 
45 ºC, and the nanoparticles were then redispersed in 
an ultrasonication bath FRQ-1008T (Front, Hangzhou, 
China). The nanoparticles were collected by centrifugation 
at 10000 g for 10 min (Sigma, Harz, Germany), followed 
by washing twice with ethanol and deionized water. 
N-hydroxysuccinimide ester of biotin (NHS-biotin) was 
prepared according with the method described by Xu 
et al. (2007). NHS-biotin 5 mg was dissolved in 0.1 M 
carbonate/bicarbonate buffer (pH9.0, 1.0 mL) and the 
stirred DTX-BSA-NPs suspension was added. It took 
16 h for reaction. The carboxylic groups of NHS-biotin 
were conjugated with the amino groups of the BSA-NPs 
under alkaline conditions. With centrifuged at 8000 g for 
10 min twice, the unassociated NHS-biotin in the mixture 
was then removed. Followed by freeze-drying (Scientz-
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10N, NingBo, China) under a condition of controlled 
temperature (-40 ºC for 24 h followed by -70 ºC for 72 h) 
and pressure (1 pa) using 5% mannitol as a freeze-drying 
agent, the DTX-BIO-BSA-NPs were obtained.
Morphology, particle size, and zeta potential of 
the DTX-BIO-BSA-NPs
A suitable amount of the lyophilized sample was 
dispersed in water. A drop of the solution was dropped on 
a round coverslip then blow-dried with sterile wind using 
a sterile bench, which also prevented dust from affecting 
the drop. The coverslip coated with the sample was used to 
investigate the morphology by SEM (FEI Co., Eindhoven, 
The Netherlands).
DTX-BIO-BSA-NPs were dispersed in water to 
attain a concentration of 5 mg/mL. Then 3 mL of the 
solution was placed in a sample cell to detect the particle 
size by laser light scattering and the zeta potential 
using a ZetaPlus Zeta Potential Analyzer (Brookhaven 
Instruments, Holtsville, USA). The data were obtained 
from the average of three measurements.
Physical status of docetaxel and DTX-BIO-BSA-
NPs
An x-ray diffractometer (Philips, The Netherlands) 
was used to determine the physical status of docetaxel in 
the nanoparticles. The diffraction angle (2θ) was recorded 
from 3° to 80° with a scanning speed of 5°/minute. CuKa 
radiation was used as the x-ray source at 40 kV and 30 mA.
Differential scanning calorimetry (DSC)
D i f f e r e n t i a l  s c a n n i n g  c a l o r i m e t r y  i s  a 
thermoanalytical technique in which the difference in 
the amount of heat required to increase the temperature 
of a sample and reference is measured as a function of 
temperature. In this paper, Five milligrams of samples were 
sealed in the aluminum pan and investigated by differential 
scanning calorimeter (TA instruments, Wilmington, USA) 
at a temperature heating rate of 10 ℃/min that from 35 
to 350 ºC with nitrogen at a flow rate of 100 mL/min and 
pressure of 40 bar. The DSC was calibrated with indium, 
with an empty pan used as reference.
Docetaxel determination by high-performance 
liquid chromatography
The docetaxel in ethanol was examined by high-
performance liquid chromatography, i.e. a Waters liquid 
chromatograph (Waters Corporation, Milford, USA), 
consisting of a Waters 600 Controller equipped with a 
Waters 717 Plus autosampler and a Waters 2487 UV 
detector. The samples were chromatographed at 25 ºC by 
injection of a 20 mL sample into a Hypersi C18 column 
(250 mm × 4.6 mm × 5 µm, DEAIC Company, Dalian, 
China). The mobile phase was a mixture of deionized 
water and acetonitrile in a volume ratio of 53:47 (v/v). 
The elution rate was 1.0 mL/min and the wavelength was 
set at 231 nm. 
Drug release
Drug release from DTX-BIO-BSA-NPs was 
studied and compared with drug release/diffusion from 
DTX suspension using a dialysis bag method (Liu et al., 
2011). The phosphate-buffered saline (0.1 M, pH 7.4) 
at 37 ºC was used to determine the docetaxel release 
from the nanoparticles. After adding DTX-BIO-BSA-
NPs suspension (0.5 mg/mL, 2 mL, without trehalose) 
or docetaxel solution (0.05 mg/mL, 2 mL) into Slide-
A-Lyzer dialysis cassettes (Sigma-Aldrich, St. Louis, 
USA), the dialysis cassettes were then immersed in 
a 250 mL beaker containing 200 mL release buffer, 
which was placed in an incubator shaker (Jiangsu Jintan 
Medical Instruments Co., Ltd., Jintan, China) at 37 ºC 
and 120 rpm. Later, with drawn from the beaker, 50 mL 
release buffer was replaced with 50 mL fresh release 
buffer by regular intervals. Each collected release buffer 
sample was concentrated to 1 mL by rotary evaporator, 
docetaxel was resolved by high-performance liquid 
chromatography and extracted from the removed medium 
after dividing into the organic phase. After being added 
to the medium, 5 mL chloroform was fully vortexed for 5 
min and allowed to stand for 15 min for phase separation. 
Upon phase separation, the denser organic chloroform 
layer was carefully partitioned from the aqueous 
buffer phase and permitted to evaporate at the indoor 
temperature overnight. The dried sample containing 
docetaxel was then dissolved in 4 mL of methanol and 
analyzed by high-performance liquid chromatography. It 
was plotted to a profile showing cumulative drug release 
on the basis of time. And each diffusion experiment was 
operated repeatedly in triplicate, the average values and 
normal deviations were calculated in detail.
In vitro cellular uptake
Human breast cancer cell line MCF-7 were used for 
studying the in vitro cellular uptake of the DTX-BSA-
NPs and DTX-BIO-BSA-NPs labeled with fluorescein 
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isothiocyanate (FITC) and Lyso-Tracker Red. MCF-7 
cells were plated in 6-well transparent plates of 300, 000 
cells per well, and incubated for 24 hours before labeling 
with FITC and Lyso-Tracker Red. After labeling with 
FITC and Lyso-Tracker Red for 2 hours at 37 ºC, the cells 
were observed by confocal laser scanning microscopy 
(Nikon, Tokyo, Japan) with fluorescence view imaging 
software.
Cytotoxic activities
To evaluate the cytotoxicity of DTX-BIO-BSA-
NPs and free docetaxel, MTT assay was used to test five 
different concentrations (1.25 nM, 12.5 nM, 125 nM, 
1.25 µM and 12.5 µM) of DTX-BIO-BSA-NPs and 
docetaxel against MCF-7 cells, SGC7901 cells, LS-
174T cells and A549 cells at 48 h, and compared the 
cytotoxic ity between the DTX-BIO-BSA-NPs and 
free docetaxel. MCF-7 (Human breast cancer cell 
line), SGC7901 (human gastric carcinoma cell line), 
LS-174T (human colon adenocarcinoma cell line) and 
A549 (human lung adenocarcinoma cell) were obtained 
from the Harbin Tumor Institute (Harbin, Heilongjiang, 
China). All cells were cultured in RPMI 1640 containing 
10% fetal bovine serum, 100 U/mL penicillin and 100 μg/
mL streptomycin at 37 ºC in a humidified 5% CO2 
incubator. Cells (50,000 per well) were seeded in 96-
well tissue culture plates for 12 h and were then treated 
with the DTX-BIO-BSA-NPs of different concentration 
or docetaxel control solution for 48 h. The media were 
then removed and cells were washed with PBS. An MTT 
assay was performed by adding 10 μL MTT reagent 
(5 mg/mL) to each well and cells were then incubated 
for 4 h, after which culture media were replaced with 
150 μL of DMSO. Light absorbance of the solution 
was measured at 492 nm using a multi-plate reader 
(Awareness Technologies, Palm City, USA). The cell 
inhibitory rate was calculated as follows: inhibition rate 
= [(Abs492control cells -Abs492treated cells)/Abs492control cells]×100 %. 
All assays were done with six parallel replicates. Cell 
viability at different concentrations of compounds was 
plotted and 50% inhibition of growth was calculated as 
IC50.
Statistical analysis of the data
Data are presented as the mean ± standard deviation 
for all treatments. Student’s t-test was used to evaluate the 
significance of differences between the treated and control 
groups. A value of p < 0.05 was considered significant.
RESULTS AND DISSCUSSION
Morphology, particle size and zeta-potential of 
DTX-BIO-BSA-NPs 
Particle size is an important aspect for the passive 
targeting of nanoparticles (Stylianopoulos, 2013). 
Scanning electron microscopy (SEM) studies were carried 
out to determine the size and shape of nanoparticle, the 
images of which are shown in Figure 1. Raw docetaxel 
presented as irregular blocks, with a particle size ranging 
from 1 to 10 μm (Figure 1A). DTX-BSA-NPs and 
DTX-BIO-BSA-NPs exhibit a nearly spherical shape 
dispersed evenly (Figure 1B and 1C), consistent with 
the report of Zhu et al. (2016). The freeze-dried powder 
and aqueous dispersion of the powder are shown in 
Figure 1D. This image demonstrates that the freeze-dried 
powder reconstitutes well in solution, with a transparent 
opalescence and uniform state observable.
The dispersion of DTX-BIO-BSA-NPs in water was 
studied to measure the stability of the solution after 8 hours 
at a temperature of 25 ºC. The particle size was always 
lower than 200 nm after redissolution with water during 
studied times as presented in Table I. DTX-BIO-BSA-
NPs are small enough for the particles to accumulate in 
tumor tissue selectively via the enhanced permeation and 
retention effect (Nichols, Bae, 2014; Araki et al., 2015). 
Restricting the size of nanoparticles to a range between 
100-200 nm enhances extravasation from tumor blood 
microvessels as well as interstitial transport, leading to 
the accumulation and retention of nanoparticles in solid 
tumors (Vardhan et al., 2017).
Zeta potential is defined as the difference of 
electrical potential between the surface of the cells and 
the bulk-surrounding medium. The surface charge has 
important effect on the stability of nanoparticles in solution 
(Ye et al., 2016). In our experiments, the zeta potentials 
were -29.51, -28.54, -36.54, -36.08 and -27.56 mV 
for 0, 1, 2, 4 and 8 hours, respectively (Table I), and 
the polydispersity index (PDI) was stable in the range 
between 0.170 - 0.178. The phenomena of particle reunion, 
precipitation, and stratification did not occur when the 
solution was stored after 8 hours and the dispersion 
appeared equally distributed. Lower PDI indicated good 
dispersibility, a prerequisite of good stability. Higher zeta 
potential supported that the DTX-BIO-BSA-NPs did 
not aggregate much in the aqueous state in general and 
physiologically-relevant media in particular. Therefore, 
the DTX-BIO-BSA-NPs dispersion demonstrated good 
stability over the 8-hour observation period.
The x-ray diffraction spectrum of docetaxel and 
Preparation, characterization, and antiproliferative activities of biotin-decorated docetaxel-loaded bovine serum albumin nanoparticles
Braz. J. Pharm. Sci. 2018;54(2):e17295 Page 5 / 11
freeze-dried DTX-BIO-BSA-NPs is shown in Figure 2. 
The disappearance of the characteristic peak (2θ=7.84°, 
12.36°, 16.58°) of docetaxel in the DTX-BIO-BSA-
NPs suggested that docetaxel was in an amorphous or 
disordered crystalline phase in the solid solution state. In 
addition, the DSC curves of samples (Figure 3) showed 
there is a peak at 222 ºC in the docetaxel curve which 
stands for docetaxel melting point peak in its crystalline 
form. This peak is not observed in DTX-BIO-BSA-NPs, 
which further demonstrated that docetaxel was in an 
amorphous or disordered crystalline state. (Musumeci et 
al., 2006; Yallapu et al., 2010). 
In vitro drug release
In vitro drug release studies are crucial to mimic the 
release of drug in a physiological environment. In vitro 
release of docetaxel from pure drug suspension and DTX-
BIO-BSA-NPs were performed in PBS (pH 7.4). Among 
the experimental methods available for determining the in 
vitro release pattern of docetaxel from docetaxel suspension 
and DTX-BIO-BSA-NPs, the dialysis bag method is the 
most suitable. The dialysis bag retains the nanoparticles and 
allows the diffusion of free drug into release media, where 
samples were withdrawn from and analysed (Zuo et al., 
TABLE I - Particle size, zeta potential and polydispersity index changes of DTX-BIO-BSA-NPs over 8 hours
Redissolution 
time (h)
Mean diameter ± SD 
(nm)
Zeta potential  
(mV)
Polydispersity
0 
1 
2 
4 
8
166.9 ± 23.8 
160.3 ± 25.6 
159.0 ± 21.4 
176.1 ± 23.0 
184.8 ± 24.2
- 29.51 ± 1.66 
- 28.54 ± 1.93 
- 36.54 ± 1.77 
- 36.08 ± 0.87 
- 27.56 ± 1.79
0.170 ± 0.016 
0.176± 0.012 
0.178 ± 0.010 
0.177 ± 0.010 
0.171 ± 0.010
FIGURE 1 - Characterization of DTX, DTX-BSA-NPs and DTX-BIO-BSA-NPs. Scanning electron microscopic images of (A) raw 
docetaxel (magnification: 5000×). (B) DTX-BSA-NPs (magnification: 20000×). (C) DTX-BIO-BSA-NPs (magnification: 30000×). 
(D) Reconstitution appearance of DTX-BIO-BSA-NPs solution (left) and freeze-dried DTX-BIO-BSA-NPs powder (right).
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2016). The in vitro drug release profiles were represented 
as a cumulative percentage of drug released with respect to 
time. The in vitro drug release profiles of the DTX-BIO-
BSA-NPs in PBS (pH7.4) in the first 4 days are illustrated 
in Figure 4. The docetaxel release from the DTX-BIO-
BSA-NPs is a complex process, which could be attributed 
to docetaxel diffusion in the bovine serum albumin carrier 
followed by BSA degradation. As shown in Figure 4, the 
free drug was found to release completely within 12 hours, 
reflecting the diffusion profile of free drug through the 
dialysis membrane. Similar results were reported by Liu 
and co-workers (Liu et al., 2016). In comparison, the drug 
release from DTX-BIO-BSA-NPs presented sustained 
release pattern which demonstrated the potential for 
prolonging therapeutic exposure time. For example, an 
initial slow release from DTX-BIO-BSA-NPs of 29.1% in 
the first 8 hours can be observed. In the following 28 hours, 
burst release increased release to 59.0%, in a sustained 
manner, which provides the possibility to continuously 
fight against cancer cells, resulting in decreased cancer cell 
viability. The cumulative release of DTX-BIO-BSA-NPs 
(81.6%) was less than that of docetaxel (89.9%) after 4 days, 
attributed to the docetaxel being well encapsulated in the 
rigid core of DTX-BIO-BSA-NPs. A cumulative release of 
81.6% after 4 days shows that the nanoparticle formulation 
reaches almost full release of docetaxel. The generally 
sustained and controlled release profile of docetaxel 
facilitates the application of nanoparticles for the delivery 
of anticancer drugs (Gan, Chien, Feng, 2010).
In vitro cellular uptake
The therapeutic effects of the drug-loaded 
FIGURE 2 - The X-ray diffraction spectrum of docetaxel and 
freeze-dried DTX-BIO-BSA-NPs. A, docetaxel; B, docetaxel-
loaded biodegradable bovine serum albumin nanoparticles 
with biotin decoration and trehalose. C, docetaxel-loaded 
biodegradable bovine serum albumin nanoparticles with biotin 
decoration; D, docetaxel-loaded biodegradable bovine serum 
albumin nanoparticles.
FIGURE 3 - The differential scanning calorimetry of docetaxel 
and freeze-dried DTX-BIO-BSA-NPs. DTX, docetaxel; 
DTX-BIO-BSA, docetaxel-loaded biodegradable bovine 
serum albumin nanoparticles with biotin decoration; DTX-
BSA-BIO+trehalose (TRE), docetaxel-loaded biodegradable 
bovine serum albumin nanoparticles with biotin decoration 
and trehalose.
FIGURE 4 - In vitro docetaxel release profile from DTX-BIO-
BSA-NPs and docetaxel (TaxoereTM). Phosphate-buffered 
saline (0.1 M, pH=7.4) was selected as the release medium. The 
nanoparticle dispersion was put in an orbital shaker and shaken 
at 120 rpm at 37 ºC. High-performance liquid chromatography 
was performed to measure the released drug concentration.
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nanoparticles would depend on internalization and 
sustained retention of the nanoparticles by the diseased 
cells. The in vitro research could provide some preliminary 
evidence to display the advantages of the nanoparticle 
formulation in comparison with the free drug. The 
cellular uptake of DTX-BSA-NPs and DTX-BIO-BSA-
NPs labeled by fluorescein isothiocyanate (a fluorescent 
probe) was examined to demonstrate internalization 
of the nanoparticles into cells and the targeting effects. 
Internalization of the DTX-BIO-BSA-NPs was visualized 
by confocal laser scanning microscopy. In Figure 5 (A-
C), the fluorescence from the nanoparticles internalized 
in cells is shown. Figure 5 (B and C) shows the images 
of the cells incubated for 4 h with DTX-BSA-NPs and 
DTX-BIO-BSA-NPs. A significant fluorescence difference 
between DTX-BSA-NPs and DTX-BIO-BSA-NPs can 
be observed. The results show that the biotin-conjugated 
nanoparticles (DTX-BIO-BSA-NPs) had better target 
delivery than nanoparticles without biotin conjugation 
(DTX-BSA-NPs). High-affinity biotin-binding protein 
was characterized in human breast cancer cell line MCF-
7, and biotin-avidin binds to the membrane fraction that 
cross reacts with the anti-intestines-specific membrane 
antigen antibody. The results of Nateghian et al. (2016) 
demonstrated that biotin-decorated docetaxel-loaded 
human serum albumin conjugates were more powerful 
in the reduction in tumor size and increased the survival 
rate when compared to free docetaxel. Therefore, we 
firmly believe that the DTX-BIO-BSA-NPs with smaller 
hydrodynamic size would have higher cellular uptake 
efficiency.
Antiproliferative efficacy of DTX-BIO-BSA-NPs 
against MCF-7 cells, SGC7901 cells, LS-174T cells 
and A549 cells in vitro
As shown in Figure 6, the antiproliferative effect 
of both DTX-BIO-BSA-NPs and free docetaxel against 
all tested cells were no more than 15% at 12.5 nm 
concentration, and about 80% at 1.25 µm concentration, 
indicating that both cytotoxicity profiles were similar. 
The drug concentration at which 50% of cells have been 
killed, IC50 values, of docetaxel and DTX-BIO-BSA-NPs 
was respectively, 0.43 ± 0.04 mM and 0.26 ± 0.07 mM 
for MCF-7 cells (p<0.05, docetaxel vs. DTX-BIO-BSA-
NPs), 0.46 ± 0.04 mM and 0.23 ± 0.06 mM for SGC7901 
cells (p<0.01), 0.34 ± 0.04 mM and 0.21 ± 0.04 mM for 
LS-174T cells (p<0.05), and 0.42 ± 0.04 mM and 0.27 ± 
0.03 mM for A549 cells (p<0.01). Consistent with Mirzaie 
et al. (2016), the cytotoxicity of DTX-BIO-BSA-NPs was 
significant higher that of docetaxel. Overall, the results 
clearly demonstrate that DTX-BIO-BSA-NPs are more 
effective against cancer cells than free docetaxel. The higher 
cytotoxicity of DTX-BIO-BSA-NPs can be attributed to 
synergistic combination of different mechanisms. DTX-
BIO-BSA-NPs were adsorbed onto the cell surface leading 
to an increase in drug concentration near the cell membrane, 
thus generating a concentration gradient that promotes the 
drug influx into the cell (Fonseca, Simoes, Gaspar, 2002). 
Cancerous cells exhibit enhanced endocytic activity and 
internalize the polymeric nanoparticles in the interior of the 
cell leading to an increase in drug concentration. In addition, 
free DTX molecules, are transported out by P-glycoprotein 
FIGURE 5 - Confocal laser scanning microcopy images show the internalization of fluorescent nanoparticles in cells. (A) MCF-7 
cells with no drug incubation. (B) MCF-7 cells incubated with DTX-BSA-NPs for 2 h. (C) MCF-7 incubated with DTX-BIO-
BSA-NPs for 2 h. DTX-BIO-BSANP, docetaxel-loaded biodegradable bovine serum albumin nanoparticles with biotin decoration; 
DTX-BSA-NPs, docetaxel-loaded biodegradable bovine serum albumin nanoparticles.
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(P-gp) pumps while drug-loaded nanoparticles are taken up 
by cells through an endocytosis pathway. Thus, it results 
in a higher cellular uptake of the entrapped drug, thereby 
enabling them to escape the effect of P-gp pumps (Panyam, 
Labhasetwar, 2003). 
As a nanoparticle formulations are expected to 
reduce the side effects caused by docetaxel and improve its 
cellular uptake, the docetaxel-loaded nanoparticles DTX-
BIO-BSA-NPs could be an ideal anticancer medicine for 
the targeted therapy.
CONCLUSION
In this study, nanoparticles of biotin-conjugated 
water-insoluble docetaxel-loaded bovine serum albumin 
have been successfully synthesized and characterized. 
The nanoparticles showed appropriate particle size, 
desired surface properties, high stability in favor of 
cellular uptake, and can be targeted specifically to cancer 
cells. DTX-BIO-BSA-NPs also exhibited enhanced 
antiproliferative effect in comparison to free docetaxel 
against tumor cells. The results of this study bolsters 
the validity of a novel DTX-BIO-BSA-NPs formulation 
prepared by desolvation technique using bovine serum 
albumin as carrier for cancer therapy, and represents a 
promising approach for nanoparticulate delivery systems 
for cytostatic agent delivery.
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